NewLink Genetics to Present at the 33rd Annual J.P. Morgan Healthcare Conference

AMES, Iowa, Jan. 7, 2015 (GLOBE NEWSWIRE) -- NewLink Genetics Corporation (Nasdaq:NLNK) today announced that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the 33rd Annual J.P. Morgan Healthcare Conference in San Francisco, on Wednesday, January 14, 2015 at 4:00 p.m. PT. The presentation will not be webcast.

About NewLink Genetics Corporation

NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immuno-oncology products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit

CONTACT: Jack Henneman Chief Financial Officer (515) 598-2561

Source:NewLink Genetics Corporation